<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Wuxi Apptec Co Ltd — News on 6ix</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd</link>
<description>Latest news and press releases for Wuxi Apptec Co Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 19 Jan 2026 00:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/wuxi-apptec-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836426f78dffbe2df14facc.webp</url>
<title>Wuxi Apptec Co Ltd</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd</link>
</image>
<item>
<title>WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-receives-double-rating-000000915</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-receives-double-rating-000000915</guid>
<pubDate>Mon, 19 Jan 2026 00:00:00 GMT</pubDate>
<description>WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Project). This recognition, which represents CDP's highest rating in each category, underscores WuXi AppTec's achievements in climate change and water resource management and its ongoing commitm</description>
</item>
<item>
<title>WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-issues-positive-profit-093000020</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-issues-positive-profit-093000020</guid>
<pubDate>Mon, 12 Jan 2026 09:30:00 GMT</pubDate>
<description>WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full year of 2025, disclosing forecasts of key operational data, with revenue from Continuing Operations growing by approximately 21.4% year-over-year.</description>
</item>
<item>
<title>WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-receives-frost-sullivans-020000362</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-receives-frost-sullivans-020000362</guid>
<pubDate>Thu, 20 Nov 2025 02:00:00 GMT</pubDate>
<description>Frost & Sullivan is pleased to announce that WuXi AppTec has received the 2025 Global Company of the Year Recognition in the contract research, development, and manufacturing organization (CRDMO) industry for its outstanding achievements in enabling innovation, operational excellence, and customer impact. This recognition underscores WuXi AppTec's contribution to driving scientific and technological advancement through an integrated, end-to-end CRDMO model, enabling customers and partners worldw</description>
</item>
<item>
<title>WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-receives-frost-sullivans-000000534</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-receives-frost-sullivans-000000534</guid>
<pubDate>Thu, 20 Nov 2025 00:00:00 GMT</pubDate>
<description>WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been recognized by Frost & Sullivan with the 2025 Global Company of the Year Award in the CRDMO industry. This marks the ninth consecutive year that WuXi AppTec has received this distinguished honor, underscoring the company's ongoing achievements in enabling innovation and operational excellence for its customers.</description>
</item>
<item>
<title>WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-looks-extend-crdmo-090000216</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-looks-extend-crdmo-090000216</guid>
<pubDate>Tue, 28 Oct 2025 09:00:00 GMT</pubDate>
<description>WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northwest Saudi Arabia and the Ministry of Health of the Kingdom of Saudi Arabia (MOH).</description>
</item>
<item>
<title>WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-achieves-strong-double-075300511</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-achieves-strong-double-075300511</guid>
<pubDate>Sun, 26 Oct 2025 07:53:00 GMT</pubDate>
<description>WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first three quarters ending September 30, 2025 ("Reporting Period"):</description>
</item>
<item>
<title>WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-implements-first-interim-000000267</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-implements-first-interim-000000267</guid>
<pubDate>Mon, 22 Sep 2025 00:00:00 GMT</pubDate>
<description>WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends.</description>
</item>
<item>
<title>WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-awarded-gold-medal-120000546</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-awarded-gold-medal-120000546</guid>
<pubDate>Mon, 08 Sep 2025 12:00:00 GMT</pubDate>
<description>WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has received the Gold Medal by EcoVadis sustainability rating for the second consecutive year. This achievement reflects WuXi AppTec's commitment to sustainability and its ongoing efforts to integrate environmental and social responsibilities into the Company's business strategies and operations.</description>
</item>
<item>
<title>WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-completes-second-rmb1-000000327</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-completes-second-rmb1-000000327</guid>
<pubDate>Thu, 28 Aug 2025 00:00:00 GMT</pubDate>
<description>WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently announced the completion of its second RMB1.0 billion A-share repurchase program in 2025 to enhance shareholder value, with all repurchased shares to be cancelled.</description>
</item>
<item>
<title>WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-named-constituent-ftse4good-000000470</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-named-constituent-ftse4good-000000470</guid>
<pubDate>Wed, 06 Aug 2025 00:00:00 GMT</pubDate>
<description>WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion in the FTSE4Good Index Series for the third consecutive year. This recognition underscores the Company's ongoing commitment to sustainable development and its efforts to build a healthier, more sustainable world.</description>
</item>
<item>
<title>WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-achieves-strong-growth-094800197</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-achieves-strong-growth-094800197</guid>
<pubDate>Mon, 28 Jul 2025 09:48:00 GMT</pubDate>
<description>WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first half ending June 30, 2025 ("Reporting Period"):</description>
</item>
<item>
<title>WuXi AppTec Issues Positive Profit Alert for the First Half of 2025</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-issues-positive-profit-000000930</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-issues-positive-profit-000000930</guid>
<pubDate>Fri, 11 Jul 2025 00:00:00 GMT</pubDate>
<description>WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-to-end new drug R&D and manufacturing services, has issued a Positive Profit Alert for the first half of 2025 and disclosed key operational data forecasts.</description>
</item>
<item>
<title>WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-provides-updates-q2-024100536</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-provides-updates-q2-024100536</guid>
<pubDate>Tue, 08 Jul 2025 02:41:00 GMT</pubDate>
<description>WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently provided updates to investors on the status of its A-share repurchase and H-share acquisition activities in Q2 2025.</description>
</item>
<item>
<title>WuXi AppTec Receives MSCI ESG AAA Leader Rating</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-receives-msci-esg-120800327</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-receives-msci-esg-120800327</guid>
<pubDate>Mon, 07 Jul 2025 12:08:00 GMT</pubDate>
<description>WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its latest annual Environmental, Social, and Governance (ESG) ratings. This is the first time WuXi AppTec has achieved the AAA rating, making it the first A-share listed company in the life science industry to reach this milestone. This achievement un</description>
</item>
<item>
<title>WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-nantong-receives-2025-000000789</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-nantong-receives-2025-000000789</guid>
<pubDate>Fri, 27 Jun 2025 00:00:00 GMT</pubDate>
<description>WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site (Phase I) has been recognized as the Popular Choice Winner in the "Factory & Warehouse" category at the 2025 Architizer A+Awards. This recognition underscores WuXi AppTec's commitment to creating innovative, human-centric workplaces that empower employees and support customers in deliv</description>
</item>
<item>
<title>WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-earns-sbti-validation-000000080</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-earns-sbti-validation-000000080</guid>
<pubDate>Wed, 18 Jun 2025 00:00:00 GMT</pubDate>
<description>WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near-term science-based emissions reduction targets. The validation of these targets affirms that the Company's planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature rise to 1.5°C, underscoring WuX</description>
</item>
<item>
<title>WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-recognized-extel-2025-120000885</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-recognized-extel-2025-120000885</guid>
<pubDate>Mon, 16 Jun 2025 12:00:00 GMT</pubDate>
<description>WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the Top 10 "Most Honored Companies" in new rankings from Extel (formerly known as Institutional Investor).</description>
</item>
<item>
<title>WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-q1-2025-revenue-093300338</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-q1-2025-revenue-093300338</guid>
<pubDate>Mon, 28 Apr 2025 09:33:00 GMT</pubDate>
<description>WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first quarter ending March 31, 2025 ("Reporting Period"):</description>
</item>
<item>
<title>WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptecs-changzhou-taixing-api-000000310</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptecs-changzhou-taixing-api-000000310</guid>
<pubDate>Tue, 01 Apr 2025 00:00:00 GMT</pubDate>
<description>WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstra</description>
</item>
<item>
<title>WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs</title>
<link>https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-revenue-profit-achieved-121900675</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-apptec-co-ltd/news/wuxi-apptec-revenue-profit-achieved-121900675</guid>
<pubDate>Mon, 17 Mar 2025 12:19:00 GMT</pubDate>
<description>WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the year ending December 31, 2024 ("Reporting Period"):</description>
</item>
</channel>
</rss>